HBK Capital Management

Resilient Network Systems specializes in contextual access management software that enhances secure data sharing and organizational connectivity. The company has developed a new class of Internet servers that extend the reach of the Internet to protected data and applications. Their software includes traditional features such as single sign-on and multi-factor authentication, while also introducing innovative methods for establishing trust and granting content owners customized control over their data usage. Resilient Network Systems' approach allows for the brokering and enforcement of policies between all parties involved in a transaction, ensuring that security and authentication measures are in place before any data exchange occurs. This capability not only safeguards valuable and private content but also supports businesses in scaling their operations effectively across their ecosystems.

EUSA Pharma, founded in March 2006 and headquartered in the UK, is a profitable specialty pharmaceutical company that operates globally with a focus on oncology and other critical diseases. The company markets a portfolio of five approved specialty hospital products, including Caphosol®, Xenazine®, Collatamp®, Custodiol®, and Fomepizole®, along with several named-patient products. EUSA Pharma is dedicated to addressing rare diseases and conditions such as oral mucositis, a common side effect of cancer treatments. The company has submitted a Marketing Authorization Application for FOTIVDA (tivozanib HCL) as a first-line therapy for renal cell carcinoma. With plans to expand its portfolio through acquisitions and in-licensing, EUSA Pharma's operations extend across Europe and the USA, supported by a network of commercial partners in Europe, the Middle East, Asia, and Latin America, making its products available in approximately 40 countries worldwide. The company is led by an experienced management team with a strong track record in the specialty pharmaceutical sector.